Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC “capitulate”?

Research output: Contribution to journal › Editorial › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	S321-S325
Journal	Translational Lung Cancer Research
Volume	7
DOIs	https://doi.org/10.21037/TLCR.2018.12.05
State	Published - Dec 2018

ASJC Scopus subject areas

@article{b855ffebc17c4f0482da46fb42acf06b,

title = "Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC “capitulate”?",

author = "Brian Ko and Balazs Halmos",

year = "2018",

month = dec,

doi = "10.21037/TLCR.2018.12.05",

language = "English (US)",

volume = "7",

pages = "S321--S325",

journal = "Translational Lung Cancer Research",

issn = "2218-6751",

publisher = "Society for Translational Medicine (STM)",

}

TY - JOUR

T1 - Capmatinib and gefitinib combination therapy

T2 - will EGFR-mutated MET-dysregulated NSCLC “capitulate”?

AU - Ko, Brian

AU - Halmos, Balazs

PY - 2018/12

Y1 - 2018/12

UR - http://www.scopus.com/inward/record.url?scp=85082978758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85082978758&partnerID=8YFLogxK

U2 - 10.21037/TLCR.2018.12.05

DO - 10.21037/TLCR.2018.12.05

M3 - Editorial

AN - SCOPUS:85082978758

SN - 2218-6751

VL - 7

SP - S321-S325

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

ER -